TAT and Stroke: Given that, unlike the L-amino acid NA-1 peptide, a D-amino acid modified version of NA-1 (D-Tat-L-2B9c) with increased proteolytic stability in vitro, also retains neuroprotective properties when co-administered with tPA in a stroke model [8], we anticipate the same will be true for R18D.